Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development expenses	$ 5,830,999	$ 6,704,164
General and administrative expenses	3,274,759	3,393,463
Total operating expenses	9,105,758	10,097,627
Loss from operations	(9,105,758)	(10,097,627)
Interest income (expenses), net
Interest income	377,849	668,895
Interest expense	(930,878)	(1,174,745)
Interest income (expenses), net	(553,029)	(505,850)
Loss before income taxes	(9,658,787)	(10,603,477)
Benefit for income taxes	1,169,820	0
Net loss	(8,488,967)	(10,603,477)
Comprehensive loss	$ (8,488,967)	$ (10,603,477)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.21)	$ (0.3)
Net loss per share, diluted (in dollars per share)	$ (0.21)	$ (0.3)
Weighted average common shares outstanding, basic (in shares)	40,521,001	34,815,870
Weighted average common shares outstanding, diluted (in shares)	40,521,001	34,815,870